Lyell Immunopharma (LYEL) Cash from Investing Activities (2020 - 2026)

Lyell Immunopharma's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at $17.4 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 74.98% year-over-year to $17.4 million; the TTM figure through Mar 2026 stood at $2.0 million (down 98.82% YoY), while the FY2025 annual figure was $54.1 million, down 55.81% from the prior year.
• Cash from Investing Activities came in at $17.4 million for Q1 2026 at Lyell Immunopharma, up from -$31.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $152.9 million in Q2 2023 to a low of -$100.7 million in Q4 2023.
• A 5-year average of $21.6 million and a median of $22.0 million in 2024 frame the typical range for Cash from Investing Activities.
• On a YoY basis, Cash from Investing Activities climbed as much as 511.18% in 2023 and fell as far as 315.85% in 2023.
• Lyell Immunopharma's Cash from Investing Activities stood at $46.6 million in 2022, then slumped by 315.85% to -$100.7 million in 2023, then surged by 153.14% to $53.5 million in 2024, then slumped by 158.62% to -$31.4 million in 2025, then jumped by 155.41% to $17.4 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $17.4 million, -$31.4 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison